Allergen-specific immunotherapy – a key driver of growth on the allergen drugs market

allergic diseases are a serious public health problem affecting a significant proportion of the population. Their prevalence is increasing due to inadequate diagnosis and lack of effective therapeutic methods, including allergen-specific immunotherapy (ASIT). The aim of the study was to assess the Russian market of allergen preparations used for diagnosis and treatment of allergies, as well as to determine its growth factors and future prospects. Materials and methods: we analyzed domestic and foreign scientific publications, data on sales of pharmaceuticals by DSM Group. Methods of marketing, structural and comparative analysis were applied. Results: The Russian market of allergen drugs shows active growth, with sales volume reaching 257 million packs worth 2.45 billion rubles in 2024.The growth rate exceeds 50% compared to 2017-2019. Herb allergens, household allergens and tree allergens are the most in demand. At the same time, there is a shortage of domestic drugs, which account for less than 15% of the market. Conclusions: The study showed that the allergen market in Russia is actively developing, with the share of ASIT drugs exceeding 90%. However, there is still a shortage of domestic drugs for diagnosis and treatment, which requires attention from manufacturers and government agencies to improve access to effective therapies for allergic diseases.

allergens, ASIT, bronchial asthma, allergic rhinitis, atopic dermatitis